Microbiome Technology Articles & Analysis: Older
6 news found
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD ...
Last week, the Nature Group Scientific Reports journal published the top 100 most downloaded cell and molecular biology papers. This comprehensive list featured an outstanding publication from our co-founders and SAB members on Precision modification of the human gut microbiota based on selective targeting of surface-associated proteins.Importantly, it is one of the few manuscripts ...
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
ByBio-Me
Intus Biosciences, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, was recently awarded a new patent by the United States Patent and Trademark Office. The patent, U.S. Patent 10,894,990, was awarded January 19, 2021, for a “High Throughput Method For Identification and Sequencing of Unknown Microbial and Eukaryotic ...
BOSTON, MA, October 21, 2020 – DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. “This strategic acquisition delivers multi-factorial value,” said Karl Beutner, MD, PhD, Co-founder, CEO, and CMO of DermBiont. “It expands ...
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs. ...